|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:SHMT1-DLAT (FusionGDB2 ID:81144) |
Fusion Gene Summary for SHMT1-DLAT |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: SHMT1-DLAT | Fusion gene ID: 81144 | Hgene | Tgene | Gene symbol | SHMT1 | DLAT | Gene ID | 6470 | 1737 |
| Gene name | serine hydroxymethyltransferase 1 | dihydrolipoamide S-acetyltransferase | |
| Synonyms | CSHMT|SHMT | DLTA|E2|PBC|PDC-E2|PDCE2 | |
| Cytomap | 17p11.2 | 11q23.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | serine hydroxymethyltransferase, cytosoliccytoplasmic serine hydroxymethyltransferaseglycine hydroxymethyltransferaseserine hydroxymethyltransferase 1 (soluble)serine methylase | dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial70 kDa mitochondrial autoantigen of primary biliary cirrhosisE2 component of pyruvate dehydrogenase complexM2 antigen complex 70 kDa subunitdihydro | |
| Modification date | 20200315 | 20200313 | |
| UniProtAcc | . | P10515 | |
| Ensembl transtripts involved in fusion gene | ENST00000316694, ENST00000352886, ENST00000539052, ENST00000354098, | ENST00000280346, ENST00000393051, ENST00000537636, | |
| Fusion gene scores | * DoF score | 4 X 5 X 2=40 | 9 X 10 X 3=270 |
| # samples | 5 | 9 | |
| ** MAII score | log2(5/40*10)=0.321928094887362 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(9/270*10)=-1.58496250072116 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: SHMT1 [Title/Abstract] AND DLAT [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | SHMT1(18231257)-DLAT(111904205), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | SHMT1 | GO:0006544 | glycine metabolic process | 24698160 |
| Hgene | SHMT1 | GO:0006563 | L-serine metabolic process | 24698160 |
| Hgene | SHMT1 | GO:0006565 | L-serine catabolic process | 17482557 |
| Hgene | SHMT1 | GO:0009113 | purine nucleobase biosynthetic process | 11516159 |
| Hgene | SHMT1 | GO:0017148 | negative regulation of translation | 10995219 |
| Hgene | SHMT1 | GO:0035999 | tetrahydrofolate interconversion | 24698160 |
| Hgene | SHMT1 | GO:0046653 | tetrahydrofolate metabolic process | 24698160 |
| Hgene | SHMT1 | GO:0046655 | folic acid metabolic process | 11278996 |
| Hgene | SHMT1 | GO:0051289 | protein homotetramerization | 24698160 |
| Hgene | SHMT1 | GO:1904482 | cellular response to tetrahydrofolate | 24698160 |
| Fusion gene breakpoints across SHMT1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across DLAT (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS5.0 | N/A | AV697159 | SHMT1 | chr17 | 18231257 | - | DLAT | chr11 | 111904205 | - |
Top |
Fusion Gene ORF analysis for SHMT1-DLAT |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3CDS | ENST00000316694 | ENST00000280346 | SHMT1 | chr17 | 18231257 | - | DLAT | chr11 | 111904205 | - |
| intron-intron | ENST00000316694 | ENST00000393051 | SHMT1 | chr17 | 18231257 | - | DLAT | chr11 | 111904205 | - |
| intron-intron | ENST00000316694 | ENST00000537636 | SHMT1 | chr17 | 18231257 | - | DLAT | chr11 | 111904205 | - |
| intron-3CDS | ENST00000352886 | ENST00000280346 | SHMT1 | chr17 | 18231257 | - | DLAT | chr11 | 111904205 | - |
| intron-intron | ENST00000352886 | ENST00000393051 | SHMT1 | chr17 | 18231257 | - | DLAT | chr11 | 111904205 | - |
| intron-intron | ENST00000352886 | ENST00000537636 | SHMT1 | chr17 | 18231257 | - | DLAT | chr11 | 111904205 | - |
| intron-3CDS | ENST00000539052 | ENST00000280346 | SHMT1 | chr17 | 18231257 | - | DLAT | chr11 | 111904205 | - |
| intron-intron | ENST00000539052 | ENST00000393051 | SHMT1 | chr17 | 18231257 | - | DLAT | chr11 | 111904205 | - |
| intron-intron | ENST00000539052 | ENST00000537636 | SHMT1 | chr17 | 18231257 | - | DLAT | chr11 | 111904205 | - |
| intron-3CDS | ENST00000354098 | ENST00000280346 | SHMT1 | chr17 | 18231257 | - | DLAT | chr11 | 111904205 | - |
| intron-intron | ENST00000354098 | ENST00000393051 | SHMT1 | chr17 | 18231257 | - | DLAT | chr11 | 111904205 | - |
| intron-intron | ENST00000354098 | ENST00000537636 | SHMT1 | chr17 | 18231257 | - | DLAT | chr11 | 111904205 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for SHMT1-DLAT |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for SHMT1-DLAT |
| Go to FGviewer for the breakpoints of :-: - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | DLAT |
| FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links the glycolytic pathway to the tricarboxylic cycle. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for SHMT1-DLAT |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for SHMT1-DLAT |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for SHMT1-DLAT |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Tgene | DLAT | P10515 | DB00157 | NADH | Small molecule | Approved|Nutraceutical | |
| Tgene | DLAT | P10515 | DB00157 | NADH | Small molecule | Approved|Nutraceutical |
Top |
Related Diseases for SHMT1-DLAT |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | SHMT1 | C0006142 | Malignant neoplasm of breast | 1 | CTD_human |
| Hgene | SHMT1 | C0013221 | Drug toxicity | 1 | CTD_human |
| Hgene | SHMT1 | C0024302 | Reticulosarcoma | 1 | CTD_human |
| Hgene | SHMT1 | C0024304 | Lymphoma, Mixed-Cell | 1 | CTD_human |
| Hgene | SHMT1 | C0024305 | Lymphoma, Non-Hodgkin | 1 | CTD_human |
| Hgene | SHMT1 | C0024306 | Lymphoma, Undifferentiated | 1 | CTD_human |
| Hgene | SHMT1 | C0027765 | nervous system disorder | 1 | CTD_human |
| Hgene | SHMT1 | C0036341 | Schizophrenia | 1 | PSYGENET |
| Hgene | SHMT1 | C0041755 | Adverse reaction to drug | 1 | CTD_human |
| Hgene | SHMT1 | C0079740 | High Grade Lymphoma (neoplasm) | 1 | CTD_human |
| Hgene | SHMT1 | C0079741 | Lymphoma, Intermediate-Grade | 1 | CTD_human |
| Hgene | SHMT1 | C0079747 | Low Grade Lymphoma (neoplasm) | 1 | CTD_human |
| Hgene | SHMT1 | C0079757 | Diffuse Mixed-Cell Lymphoma | 1 | CTD_human |
| Hgene | SHMT1 | C0079770 | Lymphoma, Small Noncleaved-Cell | 1 | CTD_human |
| Hgene | SHMT1 | C0152013 | Adenocarcinoma of lung (disorder) | 1 | CTD_human |
| Hgene | SHMT1 | C0678222 | Breast Carcinoma | 1 | CTD_human |
| Hgene | SHMT1 | C1257931 | Mammary Neoplasms, Human | 1 | CTD_human |
| Hgene | SHMT1 | C1458155 | Mammary Neoplasms | 1 | CTD_human |
| Hgene | SHMT1 | C3714542 | Lymphoma, Diffuse | 1 | CTD_human |
| Hgene | SHMT1 | C4704874 | Mammary Carcinoma, Human | 1 | CTD_human |
| Hgene | SHMT1 | C4721532 | Lymphoma, Non-Hodgkin, Familial | 1 | CTD_human |
| Tgene | DLAT | C1855565 | Pyruvate Dehydrogenase E2 Deficiency | 4 | CTD_human;GENOMICS_ENGLAND;ORPHANET |
| Tgene | DLAT | C0034345 | Pyruvate Dehydrogenase Complex Deficiency Disease | 2 | GENOMICS_ENGLAND |
| Tgene | DLAT | C0393588 | Dystonia, Paroxysmal | 2 | GENOMICS_ENGLAND |
| Tgene | DLAT | C0013421 | Dystonia | 1 | GENOMICS_ENGLAND |
| Tgene | DLAT | C0019193 | Hepatitis, Toxic | 1 | CTD_human |
| Tgene | DLAT | C0151744 | Myocardial Ischemia | 1 | CTD_human |
| Tgene | DLAT | C0860207 | Drug-Induced Liver Disease | 1 | CTD_human |
| Tgene | DLAT | C1262760 | Hepatitis, Drug-Induced | 1 | CTD_human |
| Tgene | DLAT | C3658290 | Drug-Induced Acute Liver Injury | 1 | CTD_human |
| Tgene | DLAT | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
| Tgene | DLAT | C4279912 | Chemically-Induced Liver Toxicity | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies